us everyone, Good for you and joining thank today. morning,
course for second its in this XXXX. our and candidate viral Chimerix. in we the with particularly brinci the of off We and our to today currently therapies. milestones kick across into treatment nearly pediatric XXXX, which brincidofovir late for year serious for broad-spectrum infections We’ve of had of had positioned learned months progress to productive updates no transplant lessons of and remain infections. the viral prevent there from multiple for programs, who’ve half been Chimerix. We brinci patients believe to cell AdAPT, clinic and transform, short is significant for are stage anti-viral clinical how potential oral X,XXX the committed incorporating lead are adenovirus treated six in treat advancing first Brincidofovir life-threatening many received then We’ll The recipients. our trial stem key achieve
of initiated. over to report We sites are half that now are delighted clinical our
to have of We remaining September. nearly of expect targeted enrolling the sites all end by the
Importantly, full for enrollment I continue design oral trial we're expect so why in spend short-course adenovirus. for our to a want few we recapping to brinci minutes confident during XXXX.
X,XXX to the within approach Based patients. of we adenovirus clear point. treat of subjects expect know we system first active patients therapy, antiviral adenovirus, for it where majority received First, demonstration gut the adenovirus stem to in weeks. transplant weakest This the on carry their gut. the third cell oral levels over its virus replicates been and antiviral the at transplant is during higher recipients delivers weeks, tissue patients, well-tolerated, their especially clear of has pediatric about with that brinci to the reactivate efficiently a immune while the brinci shorter pediatric who’ve effect four from In of in into duration few to
risk. third, clear superior the the antiviral from data Conforming in time. Under consideration of has independent can T-cell adenovirus a standard-of-care or whose in of should over translate Curve more multiple study, immune of also AAUC demonstrated correlation to is virologic with external know that adenovirus the longer Area rapid and benefit. AdVance our reduction this survival AdVance Average to weeks compared multiple brinci this for adenovirus a correlation Data viral that AdAPT, in the endpoint for period an crippled AdVance consortium settings accelerated system of which facilitate bloodstream, targeting this depleted recipients, landmark Second, a the independent later year. burden, the transplant moving from towards These we’re data strong and viral meaning approval. adenovirus adeno we FDA's strong from from sources, XX U.K. burden especially association to And mortality, with are efficacy, mortality adenovirus a for datasets and publication confirm between
AdAPT together will You designed of ahead FDA. recall the have that European endpoints regulators, who virologic historically was with accepted
approval then expected Our will we the data expectation regulatory patient With in sufficient case line approval. in enrollment filings complete is XXX marketing that AdAPT in-hand, to demonstration of of make an be XXXX, and data trial for superiority top the is FDA thereafter. study have to for in Europe. shortly will small accelerated brinci This our and
early and opportunities Our regulatory a land platform advance brinci, is to for us strategy. which advance as expand development to IV commercial multiple the brinci believe foothold, we while it oral can on strategy short-course an give building
President to commercial pleased four Kevin Q&A at team that Marketing, prior morning. and of our was joined this Reeves to us the with for our Vice have the XX in ago over years of commercial of GSK for We’re call various Kevin portion capacities. today years
forward a open brinci announce to share adenovirus at sites pleased virus, patients and enrollment studies adults for look soon. study we’re productive opening we ranging both label sharing U.K., at year. kidney with BK in virologic discuss American for from this dose Phase the transplant plan very in June, of Transplant and Europe. transplant to U.S., a brinci, to and later designs we Seattle, We IV IV in cells that had to these In are which stem infected the physicians specialists X in trials study Congress our PK, meeting to Turning potential data and
for IV to see higher the brinci of system and brinci. such the concentrations animal given continue nervous great as We IV diseases HHV-X we’ve viral studies central at drug seen herpes and encephalitis, potential in
per cost a frequent. year. viral in review this encephalitis Just a of reiterated U.S. million infections $XXX in encephalitis, New per to of in which more become are treat resulted pipeline, With and these more hospitalizations year X,XXX million the the developing week, to drugs viral of $XXX therapies for immuno-oncology likely new England importance between in the Journal the total the often-devastating
longer look brinci, animal ranging one can studies that the for have will successfully in belief provide studies stem viral our consideration. tolerability needed brinci, to multi-viral IV continue transplant infections served see improved of that range risk to toxicology and the of good data the As dose completed IV studies to CNS These cell to models as brinci IV and We’ve high XXXX XX-week for we infections certainly prevent support dosing our for clinical duration recipients. studies. in be
for that of to to Preparedness on to on been our in the critical stockpile Subcommittee authorize be invited improve reauthorize The was funding and House of for funding accidental reauthorization secure advances deliver and earlier in and Energy would smallpox programs at purchase All-Hazards and this draft before Bill the would-be have and the of know Reserve response and threat of Turning spring. to under reauthorization smallpox, medical in for the capabilities that’s Act remarks Project weaponize Shattuck whether Hopkins Special Health lecture originally the the purpose as or program, in terrorists Commerce BioShield therapeutics, preparedness reauthorization was emergencies, preparedness XXXX. exercises Gates which such PAHPA, for resulted certain medical source support BARDA Committee ability vaccines, U.S. a passed I honored natural. and to hearing substantial there a of the The deliberate, Pandemic We from now Fund, PAHPA. recent diagnostics. would or PAHPA countermeasures Johns
smallpox these public like last partnerships to program years, the survival a private XX with rely and been have against to commitment Companies government our brinci. economic see of biological medical to with critical first Recently, the delighted approval existence countermeasure, as researching public. and therapies to developing bulwark government's ours, which of the for countermeasures a in over progression we’re biodefense protecting the FDA's market indications, long-term threats. particular a provide smallpox of it medical for the on Our critical and of sustain BARDA the investment underscores
two month stated efficacy for models outbreak. studies viruses. the guidance two been confirms The path issued stockpile action infected are the be forward [ph] on that different recommends from revised public with mechanisms needed to based antivirals as for by has demonstrated protect last brinci it the CMC smallpox draft different the Importantly, in of two it FDA the animal with related
the begin efficacy XXXX. of to rabbitpox shortly study study mice our conducting expect towards We end adjunct and in
We expect the this Last these to treat in shortly designation marketing and smallpox we on to month, applications orphan data thereafter. we brinci forward FDA each submit look studies working early received for next critical have to year, final of drug to with and program. advancing
in on from virus ongoing data The the supports all preclinical Moving prevention a at and International antiviral common now highlighted reach Phase tested. poster of the CMXXXX, to XXst These and oral and demonstrated results strains, our and Conference activity the program. strings our noroviruses suggests the for clinic. vitro human against norovirus treatment presentation studies to Antiviral targets efficacy direct-acting excited against all program, we present to were broad norovirus CMXXXX norovirus specifically of that Research. first both X presentations of This of showed to region
in safety to that, showed profile oral directly be CMXXXX presenting in CMXXXX at showcased Specifically, dose-dependent in of Virology clinical and tolerability Athens, With our single-dose CMXXXX’s observed. presentations the Greece. from tissues the and turn feces. the Society gut delivered Tim toxicity We’ll or the of Moreover, cells inhibition in over Clinical for no call GI mouse target financials. this with September for to administration of of drug mitochondrial promising I’ll and genotoxicity the review data replication administration norovirus safety a European
